ReviewNeuroscience letters2012
Targeted drug delivery to the peripheral nervous system using gene therapy.
Review in Neuroscience letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Review
- TET1 overexpression attenuates paclitaxel-induced neuropathic pain through rescuing KLife sciences · 2022Article
- The efficacy of GABAergic precursor cells transplantation in alleviating neuropathic pain in animal models: a systematic review and meta-analysis.The Korean journal of pain · 2022Article
- Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells.The AAPS journal · 2021Article
- Neuronal delivery of nanoparticles via nerve fibres in the skin.Scientific reports · 2021Article
- Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy.Virology : research and treatment · 2020Review
- TET1 Overexpression Mitigates Neuropathic Pain Through Rescuing the Expression of μ-Opioid Receptor and Kv1.2 in the Primary Sensory Neurons.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Article
- Long noncoding RNA (lncRNA): a target in neuropathic pain.Expert opinion on therapeutic targets · 2019Review
- Article
- Strategies for Targeted Delivery to the Peripheral Nerve.Frontiers in neuroscience · 2018Review
- Nasal application of HSV encoding human preproenkephalin blocks craniofacial pain in a rat model of traumatic brain injury.Gene therapy · 2017Article
- Article
- Effective gene expression in the rat dorsal root ganglia with a non-viral vector delivered via spinal nerve injection.Scientific reports · 2016Article
- Mechanisms of PDGF siRNA-mediated inhibition of bone cancer pain in the spinal cord.Scientific reports · 2016Article
- HSV vector-mediated GAD67 suppresses neuropathic pain induced by perineural HIV gp120 in rats through inhibition of ROS and Wnt5a.Gene therapy · 2016Article
- Current gene therapy using viral vectors for chronic pain.Molecular pain · 2015Review
- Attenuation of myogenic orofacial nociception and mechanical hypersensitivity by viral mediated enkephalin overproduction in male and female rats.BMC neurology · 2015Article
- Intraneural convection enhanced delivery of AAVrh20 for targeting primary sensory neurons.Molecular and cellular neurosciences · 2014Article
- Augmenting glial cell-line derived neurotrophic factor signaling to treat painful neuropathies.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Neuropathic cancer pain: What we are dealing with? How to manage it?OncoTargets and therapy · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Gene transfer to target delivery of neurotrophic factors to the primary sensory afferent for treatment of polyneuropathy, or of inhibitory neurotransmitters for relief of chronic pain, offers the possibility of a highly selective targeted release of bioactive molecules within the nervous system. Preclinical studies with non-replicating herpes simplex virus (HSV)-based vectors injected into the skin to transduce neurons in the dorsal root ganglion have demonstrated efficacy in reducing-pain related behaviors in animal models of inflammatory pain, neuropathic pain, and pain caused by cancer, and in preventing progression of sensory neuropathy caused by toxins, chemotherapeutic drugs or resulting from diabetes. Successful completion of the first phase 1 clinical trial of HSV-mediated gene transfer in patients with intractable pain from cancer has set the stage for further clinical trials of this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.